Core Insights - ICU Medical, Inc. reported a revenue of $540.7 million for Q4 2025, a decrease from $629.8 million in Q4 2024, indicating a year-over-year decline of approximately 14% [2] - The company experienced a GAAP net loss of $(15.7) million, or $(0.64) per diluted share, an improvement from a net loss of $(23.8) million, or $(0.97) per diluted share in the previous year [2][13] - Adjusted diluted earnings per share for Q4 2025 was $1.91, down from $2.11 in Q4 2024, while adjusted EBITDA was $98.2 million compared to $105.5 million in the same period last year [2][3] Financial Performance - Q4 2025 gross profit was $203.0 million, down from $227.3 million in Q4 2024, with a gross margin of 38%, up from 36% in the prior year [2][13] - For the full fiscal year 2025, total revenues were $2,231.3 million, a decrease from $2,382.0 million in 2024 [4] - The company’s fiscal year 2026 guidance estimates GAAP net income between $26 million to $44 million and adjusted EBITDA in the range of $400 million to $430 million [5] Product Line Performance - Revenue from consumables in Q4 2025 was $284.7 million, an increase of $16.6 million from $268.1 million in Q4 2024 [4] - Infusion systems revenue rose to $176.3 million, up by $4.6 million from $171.7 million in the same quarter last year [4] - Vital care revenue saw a significant decline, dropping to $79.7 million from $190.0 million in Q4 2024, reflecting a decrease of $110.3 million [4] Cash Flow and Balance Sheet - The company reported cash and cash equivalents of $307.963 million as of December 31, 2025, slightly down from $308.566 million a year earlier [10] - Total assets decreased to $4,050.508 million from $4,203.931 million in the previous year [11] - Current liabilities were reported at $498.861 million, down from $556.182 million in 2024 [11] Conference Call and Future Outlook - A conference call was scheduled to discuss the financial results, indicating the company's commitment to transparency and investor communication [6] - The company aims to provide quality and innovation in its medical products, focusing on growth in infusion systems and consumables [7]

Core Insights - ICU Medical, Inc. reported a revenue of $537.0 million for Q3 2025, a decrease from $589.1 million in Q3 2024, indicating a year-over-year decline of approximately 8.8% [2] - The company achieved a GAAP gross profit of $200.9 million with a gross margin of 37%, an improvement from 35% in the same period last year [2] - The net loss for Q3 2025 was $(3.4) million, significantly reduced from a net loss of $(33.0) million in Q3 2024, translating to a loss per diluted share of $(0.14) compared to $(1.35) [2][12] - Adjusted diluted earnings per share rose to $2.03 from $1.59 year-over-year, while adjusted EBITDA increased to $105.9 million from $94.8 million [2][3] Financial Performance - Revenue breakdown for Q3 2025 by product line showed: - Consumables: $285.1 million, up from $264.9 million (increase of $20.2 million) - Infusion Systems: $173.9 million, up from $159.8 million (increase of $14.1 million) - Vital Care: $78.0 million, down from $164.5 million (decrease of $86.5 million) [3] - For the nine months ended September 30, 2025, total revenue was $1,690.5 million, down from $1,752.2 million in the same period of 2024 [3] Fiscal Year Guidance - The company updated its fiscal year 2025 guidance for GAAP net loss to a range of $(8) million to $0 million, an improvement from the previous range of $(43) million to $(35) million [4] - Adjusted EBITDA guidance for the full year was revised to a range of $395 million to $405 million, up from $380 million to $390 million [4] - Diluted earnings per share guidance was also increased to a range of $7.35 to $7.65 from $6.85 to $7.15 [4] Conference Call - A conference call to discuss the third quarter 2025 financial results was scheduled for today at 4:30 p.m. ET, accessible via phone and webcast [5] Company Overview - ICU Medical is a global leader in infusion systems and high-value critical care products, focusing on quality, innovation, and value for clinical customers worldwide [6]